SCHEMBL7455306

SCHEMBL7455306

NC(=O)N(N)Cc1ccc(Oc2ccc(F)cc2)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 2/20 0.44
SCN4A P35499 1/20 0.43
PARP10 Q53GL7 2/20 0.43
LPAR1 Q92633 6/20 0.42
LPAR5 Q9H1C0 6/20 0.42
CARM1 Q86X55 1/20 0.41
PRMT6 Q96LA8 1/20 0.41
PNLIP P16233 1/20 0.41
HSPB1 P04792 1/20 0.41
MET P08581 1/20 0.41
PTGER4 P35408 1/20 0.40
PTGER2 P43116 1/20 0.40
SCN9A Q15858 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7989071 0.87 LPAR1 (0.42) NR3C1SCN4APARP10LPAR1LPAR5
SCHEMBL7459213 0.78 CARM1 (0.48) NR3C1SCN4APARP10CARM1PRMT6
SCHEMBL4991862 0.75 CARM1 (0.48) NR3C1SCN4APARP10CARM1PRMT6
SCHEMBL14656214 0.75 TTR (0.51) NR3C1SCN4ACARM1PRMT6PNLIP
SCHEMBL14662185 0.74 PPARG (0.54) CARM1PRMT6
SCHEMBL7460324 0.73 LTA4H (0.42) SCN4APARP10CARM1PRMT6PNLIP
SCHEMBL5569145 0.73 HSPB1 (0.48) NR3C1SCN4ACARM1PRMT6PNLIP
SCHEMBL3024115 0.73 PARP10 (0.67) SCN4APARP10PNLIPHSPB1MET
SCHEMBL7996091 0.73 FAAH (0.47) NR3C1SCN4APARP10CARM1PRMT6
SCHEMBL11990070 0.72 HSPB1 (0.46) CARM1PRMT6HSPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037926-A1 Sodium channel blocker compositions and the use thereof PURDUE PHARMA LTD. 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037926-A1 Sodium channel blocker compositions and the use thereof CACNA1B, CACNB2, CACNA1C NR3C1 2955/4885SCN4A 27/4885PARP10 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.